



REVA to Present at EuroPCR 2017

12-month Fantom data to be presented during Late Breaking Trials

Sydney, Australia and San Diego, California (Wednesday, 12 April 2017 AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to announce the Company’s scheduled presentations during the upcoming EuroPCR 2017 conference, which will be held May 16th through 19th in Paris, France.

REVA has been accepted to present the 12-month clinical results from its FANTOM II clinical trial during a late breaking trial (“LBT”) session on Tuesday, May 16, 2017. LBT reports are one of the most prestigious forums at the conference, focusing on the latest data of the most innovative new technologies. The Company is also sponsoring a 60-minute symposium, which will highlight the use of REVA’s *Fantom* scaffold in complex cases and provide an overview of REVA’s global clinical trial program.

Fantom is a second-generation bioresorbable scaffold that offers genuine performance advantages over the first-generation products on the market today. The differentiated ease-of-use features built into *Fantom*, including complete scaffold visibility under x-ray and a straight-forward implant procedure, will enable physicians to confidently offer scaffold treatment to patients suffering from coronary artery disease.

Fantom was recently granted European CE Mark approval and the Company’s commercial launch is underway in selected centers in Europe.

The schedule of REVA’s presentations is as follows:

Tuesday, May 16, 2017

12:52 p.m. Session: Late-Breaking Trials – Evolving BRS Technology
Room 351 *First report for the 12-month clinical outcomes of the Fantom scaffold*
Presented by Dr. Alexandre Abizaid

Wednesday, May 17, 2017

12:30 – 1:30 p.m. Symposium sponsored by REVA Medical
Room 252B *Fantom: performance gains and clinical data for a next-generation BRS*
Chairpersons: Drs. Alexandre Abizaid and Johannes Brachmann

Following the release of 12-month clinical results from the FANTOM II trial, REVA’s CEO, Ms. Reggie Groves, will be available for individual briefings with institutional investors. Interested parties may contact Mr. Jeff Warren at jeff.warren@fourhillsadvisors to arrange a meeting.

The presentation materials delivered at the conference will be available in the Investor Relations section of REVA’s website at www.revamedical.com.

About REVA

REVA is a medical device company located in San Diego, California, USA, that has developed a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s *Fantom*[®] scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to commercialize current products, develop and commercialize new products, timely and successfully complete clinical trials, obtain additional regulatory approvals, protect our intellectual property position, recruit and retain key personnel, and estimates regarding our capital requirements and financial performance. Readers should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on February 27, 2017. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

United States

Investor & Media Enquiries:

REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

Australia

Investor Enquiries:

Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

Australia

Media Enquiries:

Buchan Consulting
Rebecca Wilson
+61 3 9866 4722